Sequential Hypofractionated Radiotherapy Followed by Anti-PD-L1 Atezolizumab for SCLC
Clinical trial NCT03262454 · UNKNOWN
Trial details
- NCT number
- NCT03262454
- Sponsor
- National Cancer Center, Korea
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-01-22
- Primary completion
- 2023-02-23
- Enrollment
- 35
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.